Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor

S. M. Dudek, S. M. Camp, E. T. Chiang, P. A. Singleton, P. V. Usatyuk, Y. Zhao, V. Natarajan, Joe GN Garcia

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Novel therapeutic strategies are needed to reverse the loss of endothelial cell (EC) barrier integrity that occurs during inflammatory disease states such as acute lung injury. We previously demonstrated potent EC barrier augmentation in vivo and in vitro by the platelet-derived phospholipid, sphingosine 1-phosphate (S1P) via ligation of the S1P1 receptor. The S1P analogue, FTY720, similarly exerts barrier-protective vascular effects via presumed S1P1 receptor ligation. We examined the role of the S1P1 receptor in sphingolipid-mediated human lung EC barrier enhancement. Both S1P and FTY-induced sustained, dose-dependent barrier enhancement, reflected by increases in transendothelial electrical resistance (TER), which was abolished by pertussis toxin indicating Gi-coupled receptor activation. FTY-mediated increases in TER exhibited significantly delayed onset and intensity relative to the S1P response. Reduction of S1P1R expression (via siRNA) attenuated S1P-induced TER elevations whereas the TER response to FTY was unaffected. Both S1P and FTY rapidly (within 5 min) induced S1P1R accumulation in membrane lipid rafts, but only S1P stimulated S1P1R phosphorylation on threonine residues. Inhibition of PI3 kinase activity attenuated S1P-mediated TER increases but failed to alter FTY-induced TER elevation. Finally, S1P, but not FTY, induced significant myosin light chain phosphorylation and dramatic actin cytoskeletal rearrangement whereas reduced expression of the cytoskeletal effectors, Rac1 and cortactin (via siRNA), attenuated S1P-, but not FTY-induced TER elevations. These results mechanistically characterize pulmonary vascular barrier regulation by FTY720, suggesting a novel barrier-enhancing pathway for modulating vascular permeability.

Original languageEnglish (US)
Pages (from-to)1754-1764
Number of pages11
JournalCellular Signalling
Volume19
Issue number8
DOIs
StatePublished - Aug 2007
Externally publishedYes

Fingerprint

Lysosphingolipid Receptors
Endothelial Cells
Electric Impedance
Lung
Small Interfering RNA
Ligation
Blood Vessels
Cortactin
Phosphorylation
sphingosine 1-phosphate
Fingolimod Hydrochloride
Myosin Light Chains
Sphingolipids
Acute Lung Injury
Pertussis Toxin
Capillary Permeability
Threonine
Membrane Lipids
Phosphatidylinositol 3-Kinases
Actins

Keywords

  • Cytoskeleton
  • FTY720
  • G-coupled receptors
  • Rac
  • Sphingosine 1-phosphate
  • Vascular permeability

ASJC Scopus subject areas

  • Cell Biology

Cite this

Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. / Dudek, S. M.; Camp, S. M.; Chiang, E. T.; Singleton, P. A.; Usatyuk, P. V.; Zhao, Y.; Natarajan, V.; Garcia, Joe GN.

In: Cellular Signalling, Vol. 19, No. 8, 08.2007, p. 1754-1764.

Research output: Contribution to journalArticle

Dudek, SM, Camp, SM, Chiang, ET, Singleton, PA, Usatyuk, PV, Zhao, Y, Natarajan, V & Garcia, JGN 2007, 'Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor', Cellular Signalling, vol. 19, no. 8, pp. 1754-1764. https://doi.org/10.1016/j.cellsig.2007.03.011
Dudek, S. M. ; Camp, S. M. ; Chiang, E. T. ; Singleton, P. A. ; Usatyuk, P. V. ; Zhao, Y. ; Natarajan, V. ; Garcia, Joe GN. / Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. In: Cellular Signalling. 2007 ; Vol. 19, No. 8. pp. 1754-1764.
@article{b544c69a06404d7398d60969543fe79f,
title = "Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor",
abstract = "Novel therapeutic strategies are needed to reverse the loss of endothelial cell (EC) barrier integrity that occurs during inflammatory disease states such as acute lung injury. We previously demonstrated potent EC barrier augmentation in vivo and in vitro by the platelet-derived phospholipid, sphingosine 1-phosphate (S1P) via ligation of the S1P1 receptor. The S1P analogue, FTY720, similarly exerts barrier-protective vascular effects via presumed S1P1 receptor ligation. We examined the role of the S1P1 receptor in sphingolipid-mediated human lung EC barrier enhancement. Both S1P and FTY-induced sustained, dose-dependent barrier enhancement, reflected by increases in transendothelial electrical resistance (TER), which was abolished by pertussis toxin indicating Gi-coupled receptor activation. FTY-mediated increases in TER exhibited significantly delayed onset and intensity relative to the S1P response. Reduction of S1P1R expression (via siRNA) attenuated S1P-induced TER elevations whereas the TER response to FTY was unaffected. Both S1P and FTY rapidly (within 5 min) induced S1P1R accumulation in membrane lipid rafts, but only S1P stimulated S1P1R phosphorylation on threonine residues. Inhibition of PI3 kinase activity attenuated S1P-mediated TER increases but failed to alter FTY-induced TER elevation. Finally, S1P, but not FTY, induced significant myosin light chain phosphorylation and dramatic actin cytoskeletal rearrangement whereas reduced expression of the cytoskeletal effectors, Rac1 and cortactin (via siRNA), attenuated S1P-, but not FTY-induced TER elevations. These results mechanistically characterize pulmonary vascular barrier regulation by FTY720, suggesting a novel barrier-enhancing pathway for modulating vascular permeability.",
keywords = "Cytoskeleton, FTY720, G-coupled receptors, Rac, Sphingosine 1-phosphate, Vascular permeability",
author = "Dudek, {S. M.} and Camp, {S. M.} and Chiang, {E. T.} and Singleton, {P. A.} and Usatyuk, {P. V.} and Y. Zhao and V. Natarajan and Garcia, {Joe GN}",
year = "2007",
month = "8",
doi = "10.1016/j.cellsig.2007.03.011",
language = "English (US)",
volume = "19",
pages = "1754--1764",
journal = "Cellular Signalling",
issn = "0898-6568",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor

AU - Dudek, S. M.

AU - Camp, S. M.

AU - Chiang, E. T.

AU - Singleton, P. A.

AU - Usatyuk, P. V.

AU - Zhao, Y.

AU - Natarajan, V.

AU - Garcia, Joe GN

PY - 2007/8

Y1 - 2007/8

N2 - Novel therapeutic strategies are needed to reverse the loss of endothelial cell (EC) barrier integrity that occurs during inflammatory disease states such as acute lung injury. We previously demonstrated potent EC barrier augmentation in vivo and in vitro by the platelet-derived phospholipid, sphingosine 1-phosphate (S1P) via ligation of the S1P1 receptor. The S1P analogue, FTY720, similarly exerts barrier-protective vascular effects via presumed S1P1 receptor ligation. We examined the role of the S1P1 receptor in sphingolipid-mediated human lung EC barrier enhancement. Both S1P and FTY-induced sustained, dose-dependent barrier enhancement, reflected by increases in transendothelial electrical resistance (TER), which was abolished by pertussis toxin indicating Gi-coupled receptor activation. FTY-mediated increases in TER exhibited significantly delayed onset and intensity relative to the S1P response. Reduction of S1P1R expression (via siRNA) attenuated S1P-induced TER elevations whereas the TER response to FTY was unaffected. Both S1P and FTY rapidly (within 5 min) induced S1P1R accumulation in membrane lipid rafts, but only S1P stimulated S1P1R phosphorylation on threonine residues. Inhibition of PI3 kinase activity attenuated S1P-mediated TER increases but failed to alter FTY-induced TER elevation. Finally, S1P, but not FTY, induced significant myosin light chain phosphorylation and dramatic actin cytoskeletal rearrangement whereas reduced expression of the cytoskeletal effectors, Rac1 and cortactin (via siRNA), attenuated S1P-, but not FTY-induced TER elevations. These results mechanistically characterize pulmonary vascular barrier regulation by FTY720, suggesting a novel barrier-enhancing pathway for modulating vascular permeability.

AB - Novel therapeutic strategies are needed to reverse the loss of endothelial cell (EC) barrier integrity that occurs during inflammatory disease states such as acute lung injury. We previously demonstrated potent EC barrier augmentation in vivo and in vitro by the platelet-derived phospholipid, sphingosine 1-phosphate (S1P) via ligation of the S1P1 receptor. The S1P analogue, FTY720, similarly exerts barrier-protective vascular effects via presumed S1P1 receptor ligation. We examined the role of the S1P1 receptor in sphingolipid-mediated human lung EC barrier enhancement. Both S1P and FTY-induced sustained, dose-dependent barrier enhancement, reflected by increases in transendothelial electrical resistance (TER), which was abolished by pertussis toxin indicating Gi-coupled receptor activation. FTY-mediated increases in TER exhibited significantly delayed onset and intensity relative to the S1P response. Reduction of S1P1R expression (via siRNA) attenuated S1P-induced TER elevations whereas the TER response to FTY was unaffected. Both S1P and FTY rapidly (within 5 min) induced S1P1R accumulation in membrane lipid rafts, but only S1P stimulated S1P1R phosphorylation on threonine residues. Inhibition of PI3 kinase activity attenuated S1P-mediated TER increases but failed to alter FTY-induced TER elevation. Finally, S1P, but not FTY, induced significant myosin light chain phosphorylation and dramatic actin cytoskeletal rearrangement whereas reduced expression of the cytoskeletal effectors, Rac1 and cortactin (via siRNA), attenuated S1P-, but not FTY-induced TER elevations. These results mechanistically characterize pulmonary vascular barrier regulation by FTY720, suggesting a novel barrier-enhancing pathway for modulating vascular permeability.

KW - Cytoskeleton

KW - FTY720

KW - G-coupled receptors

KW - Rac

KW - Sphingosine 1-phosphate

KW - Vascular permeability

UR - http://www.scopus.com/inward/record.url?scp=34250616679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250616679&partnerID=8YFLogxK

U2 - 10.1016/j.cellsig.2007.03.011

DO - 10.1016/j.cellsig.2007.03.011

M3 - Article

VL - 19

SP - 1754

EP - 1764

JO - Cellular Signalling

JF - Cellular Signalling

SN - 0898-6568

IS - 8

ER -